. "9. Findings, Conclusions, and Recommendations." New Vaccine Development: Establishing Priorities: Volume II, Diseases of Importance in Developing Countries. Washington, DC: The National Academies Press, 1986.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
New Vaccine Development: Establishing Priorities, Volume II, Diseases of Importance in Developing Countries
TABLE 9.2 Benefits and Affordability of Various Vaccine Candidates
Vaccine
Annualized Present Value of Potential Health Benefits (IME units)
Vaccine
Annualized Present Value of Potential Expenditures ($ millions)
S. pneumoniae
1,363,943
Rabies (live vector virus)
15.5
Rotavirus (HPBRV)
521,852
V. cholera (attenuated live)
23.8
Malaria (monovalent)
475,205
V. cholera (inactivated)
43.6
Rotavirus (LPBRV)
450,795
E. coli (attenuated live)
69.2
Rotavirus (RMRV)
450,795
Shigella
91.6
S. typhi (Ty21a)
431,471
Yellow fever
93.0
Malaria (multivalent)
426,640
Rabies (glycoprotein)
138.7
Shigella
222,096
Rabies (Vero cell derived)
146.8
Hepatitis B
213,192
S. typhi (aa-strain)
152.2
H. influenzae b
210,943
Dengue
241.8
S. typhi (aa-strain)
194,745
M. leprae
270.6
Streptococcus group A
180,513
S. typhi (Ty21a)
358.0
E. coli (attenuated live)
145,260
H. influenzae b
526.6
E. coli (purified antigens)
126,454
Streptococcus group A
554.2
V. cholera (attenuated live)
94,986
Japanese encephalitis
614.0
M. leprae
88,481
Rotavirus (LPBVR)
655.4
V. cholera (inactivated)
65,548
Rotavirus (RMRV)
655.9
RSV (attenuated live virus)
59,559
N. meningitidis
708.1
RSV (glycoprotein)
52,412
E. coli (purified antigens)
722.3
Parainfluenza viruses
43,692
Rotavirus (HPBRV)
852.7
Rabies (Vero cell derived)
41,910
Malaria (multivalent)
856.8
Rabies (glycoprotein)
37,983
Malaria (monovalent)
967.3
Hepatitis A (attenuated live virus)
15,112
RSV (attenuated live)
982.8
Hepatitis A (polypeptide)
14,392
Hepatitis A (attenuated live)
1,058.0
N. meningitidis
13,754
Streptococcus pneumoniae
1,310.3
Yellow fever virus
11,127
Parainfluenza
1,697.1
Dengue virus
9,558
RSV (glycoprotein)
1,964.4
Rabies (live vector virus)
8,260
Hepatitis A (polypeptide)
4,029.0
Japanese encephalitis virus
3,232
Hepatitis B
8,859.3
Health benefits are expressed in units equivalent in undesirability to the death of an infant (IMEs) and are calculated using the median of IME perspectives from responding health professionals in developing countries.
